“We’re delighted to welcome Aaron to AMAG and are pleased to have his strong abilities on board at a time when business development is a core strategic focus for our company,” said Ms. Klug. “
Prior to joining AMAG, Mr. Pelta served in various positions of increasing responsibility in the business development and commercial groups at
Inducement Equity Awards
In connection with Mr. Pelta’s entering into employment with AMAG, he will be granted (i) an option to purchase 9,000 shares of common stock and (ii) 2,500 restricted stock units. The option will have an exercise price equal to the closing price of AMAG’s common stock on the grant date and will be exercisable in four equal annual installments beginning on the first anniversary of the grant date. The option will have a ten-year term and be subject to the terms and conditions of the stock option agreement pursuant to which the option will be granted. The restricted stock units will vest in three equal annual installments beginning on the first anniversary of the grant date and will be subject to the restricted stock unit agreement pursuant to which the restricted stock units will be granted. These equity awards will be granted without stockholder approval as inducements material to Mr. Pelta entering into employment with AMAG in accordance with NASDAQ Listing Rule 5635(c)(4).
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to statements regarding the contributions and responsibilities of Mr. Pelta and AMAG’s plans to pursue patient-focused therapies to build a diversified, multi-product pharmaceutical company are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.
Such risks and uncertainties include, among others, AMAG’s ability to attract and retain key employees, and the resulting disruptions to AMAG’s operations if we fail to do so and such other risks identified in AMAG’s
We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
AMAG Pharmaceuticals® is a registered trademark of
AMAG Pharmaceuticals, Inc. Linda LennoxVice President, Investor Relations & Corporate Communications 617-498-2846